Johnson Johnson AbbVie: Paths to Pharma Dominance
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Not all investors can use a backdoor Roth. This intro clarifies eligibility and the basic implementation steps.
27,669 articlesJohnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
A small board-game importer plans to manufacture Monopoly in the United States after tariffs push production home, a ...
Non-China emerging markets have moved to the forefront of global returns in 2026, delivering double-digit gains even ...
The U.S. government moved 3,940 BTC valued at about $244 million and 30,014 ETH worth roughly $53 million to Coinbase...
An academic paper analyzes UWM's 2021 broker ultimatum tied price and finds rivals shaved an average of 5 basis point...
Warren Buffett unveils a major shift in his charity strategy, moving Berkshire Hathaway’s remaining fortune toward fa...
The Russell 2000 is on track for its strongest year since 2003, outpacing the S&P 500 as AI infrastructure plays lift...
Moonshot AI unveils Kimi K3, a new open Chinese AI model that could alter the competitive balance in the AI race. Inv...
Jim Cramer advises investors to wait before buying Vertiv after a pronounced dip, arguing that selling pressure could...
Machi Big Brother’s high-stakes run appears to be nearing an end as his Hyperliquid balance drops below $1 million. T...
A mid-cap tech stock has quietly outperformed NVIDIA on a three-year price-return basis, triggering renewed interest ...
XRP is tightening like a spring as exchange inflows rise and on-chain liquidity thins. Analysts say the setup mirrors...